Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells

No abstract is available for this paper.

• Publication year

  2007

• Venue

  International Journal of Cancer

• Publication date

  2007-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.22423PMID 17266042
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro and in vivo Effects of Combination of Trastuzumab (Herceptin) and Tamoxifen in Breast Cancer

  2005cited by this paper
• Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

  2005cited by this paper
• Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

  2005cited by this paper
• Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549

  2005cited by this paper
• Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells

  2005influential reference
• Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.

  2005cited by this paper
• Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention.

  2005influential reference
• Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

  2004cited by this paper
• Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells

  2004cited by this paper
• Dominant negative interference of transcription factor AP-2 causes inhibition of ErbB-3 expression and suppresses malignant cell growth

  2004cited by this paper
• Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.

  2004cited by this paper
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• Mechanisms of tamoxifen resistance

  2004cited by this paper
• Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

  2004cited by this paper
• The deaf and the dumb: the biology of ErbB-2 and ErbB-3.

  2003cited by this paper
• Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

  2003cited by this paper
• Prognostic value of ERBB family mRNA expression in breast carcinomas

  2003cited by this paper
• Killing the messenger: short RNAs that silence gene expression

  2003cited by this paper
• The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

  2003influential reference
• ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.

  2003cited by this paper
• Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

  2003cited by this paper
• Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells

  2003cited by this paper
• Estrogen receptor phosphorylation.

  2003cited by this paper
• A Novel Single Amino Acid Deletion Caspase-8 Mutant in Cancer Cells That Lost Proapoptotic Activity*

  2002cited by this paper
• Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer

  2002cited by this paper
• Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.

  2001cited by this paper
• Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

  2001cited by this paper
• Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions.

  2001cited by this paper
• Cellular and molecular pharmacology of antiestrogen action and resistance.

  2001cited by this paper
• The Tamoxifen-responsive Estrogen Receptor α Mutant D351Y Shows Reduced Tamoxifen-dependent Interaction with Corepressor Complexes*

  2001influential reference
• Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α

  2001cited by this paper
• ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth

  2001cited by this paper
• The role of HER-2 expression in predicting response to therapy in breast cancer.

  2000cited by this paper
• Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c- jun N-terminal kinase activity

  2000cited by this paper
• Expression of c‐erbB receptors, heregulin and oestrogen receptor in human breast cell lines

  2000cited by this paper
• Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.

  2000cited by this paper
• Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

  2000cited by this paper
• Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

  2000cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

  2000cited by this paper
• Molecular markers for predicting response to tamoxifen in breast cancer patients

  2000cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

  1999influential reference
• Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization.

  1999cited by this paper
• Phosphorylation of Human Estrogen Receptor α by Protein Kinase A Regulates Dimerization

  1999cited by this paper
• The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase.

  1999cited by this paper
• erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

  1998cited by this paper
• Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase.

  1997cited by this paper
• Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

  1997cited by this paper
• Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1)

  1997cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.

  1995cited by this paper
• Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.

  1995cited by this paper
• Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase

  1995cited by this paper
• c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

  1994cited by this paper
• Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

  1992cited by this paper
• c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.

  1991cited by this paper
• Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity

  1986cited by this paper
• The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

  1986cited by this paper

• Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer

  2025cites this paper
• Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial

  2025cites this paper
• Surface plasmon resonance microscopy reveals N-glycosylation driven modulation of affinity and avidity of ErbB receptors in whole single pancreatic cancer cells

  2025cites this paper
• Patritumab deruxtecan in breast cancer treatment: a drug evaluation

  2025cites this paper
• Breakthroughs in the nanoparticle-mediated delivery of siRNA for breast cancer treatment.

  2025cites this paper
• Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway

  2025cites this paper
• HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs

  2024cites this paper
• Potential of epithelial membrane protein 3 as a novel therapeutic target for human breast cancer.

  2024cites this paper
• Immune marker expression and prognosis of early breast cancer expressing HER3.

  2024cites this paper
• Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies

  2024cites this paper
• Cytotoxicity of bismuth(III) dithiocarbamate derivatives by promoting a mitochondrial-dependent apoptotic pathway and suppressing MCF-7 breast adenocarcinoma cell invasion

  2024cites this paper
• HER3 receptor and its role in the therapeutic management of metastatic breast cancer

  2024cites this paper
• Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers

  2024cites this paper
• Long road towards effective HER3 targeting in breast cancer.

  2024cites this paper
• Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy

  2024cites this paper
• miR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer

  2024cites this paper
• A phase Ia/Ib study of novel anti‐ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer

  2023cites this paper
• Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer.

  2023cites this paper
• Targeting HER3 for cancer treatment: a new horizon for an old target

  2023cites this paper
• Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy

  2023cites this paper
• HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer

  2023cites this paper
• Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy

  2023cites this paper
• Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC

  2023cites this paper
• ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells

  2022cites this paper
• Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases

  2022cites this paper
• New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer

  2022cites this paper
• HER3 in cancer: from the bench to the bedside

  2022cites this paper
• Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer

  2022cites this paper
• Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse

  2022cites this paper
• A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization

  2021cites this paper
• Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

  2021cites this paper
• Breast Cancer Response to Therapy: Can microRNAs Lead the Way?

  2021cites this paper
• Resveratrol increases the sensitivity of multiple myeloma cells against bortezomib via Hedgehog signaling pathway

  2021cites this paper
• Neuregulin Signaling in the Tumor Microenvironment.

  2021cites this paper
• Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer

  2021cites this paper
• An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway

  2020cites this paper
• B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine

  2020cites this paper
• HER family in cancer progression: From discovery to 2020 and beyond.

  2020cites this paper
• Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.

  2020cites this paper
• Spotlight on the Granules (Grainyhead-Like Proteins) – From an Evolutionary Conserved Controller of Epithelial Trait to Pioneering the Chromatin Landscape

  2020cites this paper
• Antiproliferative and apoptotic property of andrographolide against human colon cancer DLD1 cell line.

  2019cites this paper
• Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes

  2019cites this paper
• Systemic delivery of Eg5 shRNA-expressing plasmids using PEGylated DC-Chol/DOPE cationic liposome: Long-term silencing and anticancer effects in vivo.

  2019cites this paper
• Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo.

  2019cites this paper
• Development of Effective Therapeutics Targeting HER3 for Cancer Treatment

  2019cites this paper
• Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells

  2018cites this paper
• HER3 signaling and targeted therapy in cancer

  2018cites this paper
• Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer

  2018cites this paper
• Silencing human epidermal growth factor receptor‐3 radiosensitizes human luminal A breast cancer cells

  2018cites this paper
• Understanding the biology of HER3 receptor as a therapeutic target in human cancer

  2018cites this paper
• Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers

  2018cites this paper
• Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells

  2018cites this paper
• EGFR-TKIs resistance via EGFR-independent signaling pathways

  2018cites this paper
• Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.

  2018cites this paper
• Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.

  2018cites this paper
• Synthesis of gold nanoparticles with Solanum xanthocarpum extract and their in vitro anticancer potential on nasopharyngeal carcinoma cells

  2018cites this paper
• Andrographolide Exhibits Anticancer Potential Against Human Colon Cancer Cells by Inducing Cell Cycle Arrest and Programmed Cell Death via Augmentation of Intracellular Reactive Oxygen Species Level

  2018cites this paper
• ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology

  2017cites this paper
• Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification

  2017cites this paper
• 6.01 – Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R

  2017cites this paper
• Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition

  2017cites this paper
• ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)

  2017cites this paper
• N-glycans of growth factor receptors: their role in receptor function and disease implications.

  2016cites this paper
• Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells

  2016cites this paper
• Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds

  2016cites this paper
• Disease-associated glycans on cell surface proteins.

  2016cites this paper
• Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth

  2015cites this paper
• Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model

  2015cites this paper
• ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics

  2015cites this paper
• High-throughput virtual screening, identification and in vitro biological evaluation of novel inhibitors of signal transducer and activator of transcription 3

  2015cites this paper
• Orchestration of ErbB3 signaling through heterointeractions and homointeractions

  2015cites this paper
• A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy

  2015cites this paper
• miRNA - Therapeutic tool in breast cancer? Where are we now?

  2015cites this paper
• Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.

  2015cites this paper
• Seribantumab, an Anti-ERBB3 Antibody, Delays theOnsetofResistanceandRestoresSensitivityto LetrozoleinanEstrogenReceptor-PositiveBreast

  2015cites this paper
• NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies

  2015cites this paper
• Novel HER3 and IGF-1R Peptide Mimics and Synthetic Cancer Vaccines

  2014cites this paper
• Spatial Stochastic Modeling of the ErbB Receptor Family

  2014cites this paper
• An examination of the pharmacology of HER2 inhibitor responses in cellular models of breast cancer

  2014influential citation
• Targeting of erbB3 receptor to overcome resistance in cancer treatment

  2014cites this paper
• Role of erbB3 receptors in cancer therapeutic resistance.

  2014cites this paper
• The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy

  2014cites this paper
• ZNF 217 , a candidate breast cancer oncogene amplified at 20 q 13 , regulates expression of the ErbB 3 receptor tyrosine kinase in breast cancer cells

  2014cites this paper
• Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells

  2013cites this paper
• Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer

  2013cites this paper
• HER-3 expression in HER-2-amplified breast carcinoma

  2013cites this paper
• The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

  2013cites this paper
• Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification

  2013cites this paper
• Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer*

  2013cites this paper
• Exploring the role of CD44 in tamoxifen resistant breast cancer

  2013cites this paper
• Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

  2012cites this paper
• Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines

  2012cites this paper
• Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers

  2012cites this paper
• Association of ErbB1–4 expression in invasive breast cancer with clinicopathological characteristics and prognosis

  2012cites this paper
• ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian))

  2012cites this paper
• Atlas of Genetics and Cytogenetics in Oncology and Haematology ERBB 3 ( verb-b 2 erythroblastic leukemia viral oncogene homolog 3 ( avian ) )

  2012cites this paper
• A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines

  2012cites this paper
• Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer

  2012cites this paper
• Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.

  2012cites this paper
• The role of pseudokinases in cancer.

  2012cites this paper